#PharmaInnovation #Endocrinology #CardiovascularHealth #GLP1 #Rybelsus #Semaglutide #MedicalAffairs #LifeSciences To view or add a comment, sign in Suzetrigine (Journavx) The First New Non-Opioid Analgesic in 20+ Years Historic Milestone: FDA Approves Suzetrigine, a Non-Opioid Alternative for Acute Pain In January 2025, the U.S
The primary mechanism of action involves binding to GLP-1 receptors located throughout the body, including the pancreas, brain, and gastrointestinal tract
Remember that everyone reacts differently
Their body, their lifestyle, their side effect profile, their eating patterns
In chronic kidney disease, the pivotal FLOW trial demonstrated that semaglutide 1 mg reduced the risk of major kidney events by 24% in patients with type 2 diabetes and CKD, resulting in a dedicated indication in this population
Food noise is mental